China Foreign R&D Investments Pass US But Slowdown Looming?
This article was originally published in PharmAsia News
China is said to have surpassed the US in luring foreign direct investment for R&D, with the pharmaceutical industry leading the way. However, top industry experts including RDPAC managing director Joseph Cho see caveats and the looming impact of an economic slowdown.
You may also be interested in...
Suzhou-based Innovent Bio becomes the fourth biotech from mainland China to go public in Hong Kong, and its strong first-day performance may have given the seemingly spooked market so far for such companies a shot of confidence.
A rapidly reforming policy and regulatory environment and a growing culture of innovation are encouraging capital and talent to pour into China, making it a question of when, rather than if, the payoffs will come for both consumers and investors.
The first IPOs to get away under Hong Kong's new relaxed rules for the listing of pre-revenue bioventures have seen mixed performances so far, and observers also have varying views on the likely success of the initiative, although the territory's stock exchange remains bullish as more companies line up to float.